# Jianwei YUAN

> Jianwei YUAN is a angel investor at Vertex Ventures China backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vertex Ventures China](https://shizune.co/investors/profile/vertex-ventures-china)
- Total investments: 7
- Last investment: Nov 2022
- Lead investor: 57%
- Last updated: Aug 2026

Jianwei YUAN is a angel investor at Vertex Ventures China focused on Biotechnology and Health Care. He is a partner at Vertex Ventures China. He completed his education at Fudan University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 86% |
| Health Care | 4 | 57% |
| Medical | 3 | 43% |
| Biopharma | 3 | 43% |
| Product Research | 2 | 29% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Angel | 2 | 29% |
| Series B | 2 | 29% |
| Venture - Series Unknown | 2 | 29% |
| Series A | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Primelink Bio | Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems. | $13.9M | Venture - Series Unknown | Nov 25, 2022 |  |
| Puji Bio | Puji Bio is a medical firm that develops molecular diagnostic kits and instruments for tumor diagnosis, birth defect screening, etc. | $15.7M | Angel | Jan 10, 2022 |  |
| VelaVigo | VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $50M | Angel | Nov 15, 2021 |  |
| China Immunotech | China Immunotech is a small molecule innovative drug R&D company developing immune cell therapy technologies and products. Including CAR-T and TCR-T cell therapy with independent intellectual property rights. It was founded in March 2018 by famous immunologists. | $31M | Venture - Series Unknown | Oct 11, 2021 |  |
| REJOIN Medical | REJOIN Medical specializes in sports medicine & minimally invasive orthopedic solutions for global healthcare professionals. | $15.5M | Series B | Aug 02, 2021 |  |
| Binhui Biotech | Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent Innovation Demonstration Zone. The company is committed to providing innovative products and services for the field of oncology integration (including diagnosis and treatment), and developing products andservices that have independent intellectual property rights and can compete with other manufacturers on the international stage. | $92.9M | Series B | Feb 10, 2021 |  |
| NeoX Biotech | neoX Biotech is a pharmaceutical company engaged in early-stage drug developmentbased on AI and computational biophysical technology. | $30M | Series A | Feb 02, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together
- [BAI capital](https://shizune.co/investors/profile/bertelsmann-asia-investments) — VC Fund, 1 deal together
- [Fosun Pharma](https://shizune.co/investors/profile/fosun-pharmaceutical) — VC Fund, 1 deal together
- [Honghui Capital](https://shizune.co/investors/profile/honghui-capital) — VC Fund, 1 deal together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 1 deal together
- [Kaitai Capital](https://shizune.co/investors/profile/kaitai-capital) — VC Fund, 1 deal together

## About Vertex Ventures China

VC Fund · Beijing, China

Vertex Ventures China invests in high-growth internet and technology start-ups across mainland China, and provides funding support and value-add services to portfolio companies in their growth stage. Based in Beijing and Shanghai, Vertex Ventures China collaborates with the Vertex network of ventures funds across US, Israel, Southeast Asia, andIndia, and under auspices of Vertex Holdings providing local knowledge with global perspective.

5 contacts available at Vertex Ventures China.

| Name | Title | Profile |
| --- | --- | --- |
| Choon Chong TAY | Managing Partner | https://shizune.co/investors/profile/tay-choon-chong |
| Jianwei YUAN | Partner | https://shizune.co/investors/profile/jianwei-yuan |
| Li Wei | Managing Partner | https://shizune.co/investors/profile/li-wei-7b08 |
| Ren Gang | Executive Director | https://shizune.co/investors/profile/ren-gang |
| Tianran LIU | Partner | https://shizune.co/investors/profile/tianran-liu-2da1 |

## Similar investors

### Similar stage
- [LVX Ventures](https://shizune.co/investors/profile/letsventure) — VC Fund
- [ZhenFund](https://shizune.co/investors/profile/zhenfund) — VC Fund
- [IAN Group](https://shizune.co/investors/profile/indian-angel-network) — VC Fund

## FAQ

### What does Jianwei YUAN invest in?

Jianwei YUAN invests primarily in Biotechnology, Health Care and Medical startups, most often at Angel and Series B stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jianwei YUAN last invest?

The most recent investment recorded for Jianwei YUAN closed in Nov 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co